key: cord-0978644-hj7ciyxq
authors: Suryadevara, Naveenchandra; Shrihari, Swathi; Gilchuk, Pavlo; VanBlargan, Laura A.; Binshtein, Elad; Zost, Seth J.; Nargi, Rachel S.; Sutton, Rachel E.; Winkler, Emma S.; Chen, Elaine C.; Fouch, Mallorie E.; Davidson, Edgar; Doranz, Benjamin J.; Chen, Rita E.; Shi, Pei-Yong; Carnahan, Robert H.; Thackray, Larissa B.; Diamond, Michael S.; Crowe, James E.
title: Neutralizing and protective human monoclonal antibodies recognizing the N-terminal domain of the SARS-CoV-2 spike protein
date: 2021-03-16
journal: Cell
DOI: 10.1016/j.cell.2021.03.029
sha: c6dfc8077114075d9918f57c038d4daa38d19ae8
doc_id: 978644
cord_uid: hj7ciyxq

Most human monoclonal antibodies (mAbs) neutralizing SARS-CoV-2 recognize the spike (S) protein receptor-binding domain and block virus interactions with the cellular receptor angiotensin-converting enzyme 2. We describe a panel of human mAbs binding to diverse epitopes on the N-terminal domain (NTD) of S protein from SARS-CoV-2 convalescent donors and found a minority of these possessed neutralizing activity. Two mAbs (COV2-2676 and COV2-2489) inhibited infection of authentic SARS-CoV-2 and recombinant VSV/SARS-CoV-2 viruses. We mapped their binding epitopes by alanine-scanning mutagenesis and selection of functional SARS-CoV-2 S neutralization escape variants. Mechanistic studies showed that these antibodies neutralize in part by inhibiting a post-attachment step in the infection cycle. COV2-2676 and COV2-2489 offered protection either as prophylaxis or therapy, and Fc effector functions were required for optimal protection. Thus, natural infection induces a subset of potent NTD-specific mAbs that leverage neutralizing and Fc-mediated activities to protect against SARS-CoV-2 infection using multiple functional attributes.

Since the emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) as a major threat to global public health, many studies have focused efforts on discovery of 48 potent neutralizing monoclonal antibodies (mAbs) against the spike (S) protein of SARS-CoV-2 49 (Baum et al., 2020a; Cao et al., 2020; Hansen et al., 2020; Ju et al., 2020; Liu et al., 2020a; Pinto 50 et al., 2020; Robbiani et al., 2020; Zost et al., 2020b) . The S protein exists as a trimer on the 51 surface of SARS-CoV-2 and facilitates entry of the virus into cells. The receptor binding domain 52 (RBD) situated in the S1 region of the S protein binds to human angiotensin-converting enzyme 53 2 (hACE2). The S2 region then changes conformation and inserts its fusion peptide into the 54 target cell membrane, thus triggering viral fusion and entry. Previous studies have demonstrated 55 that the RBD region is a key target for potently neutralizing antibodies (Alsoussi et al., 2020; 56 Barnes et al., 2020; Baum et al., 2020a; Hansen et al., 2020; Hassan et al., 2020; Zost et al., 57 2020a) . These studies also defined inhibition of S trimer binding to the cellular receptor ACE2 as 58 a principal mechanism of action of RBD-targeting antibodies against SARS-CoV-2, and showed 59 protection in animals against infection and disease by this class of mAbs (Baum et al., 2020a; 60 In contrast, the RBD-targeting mAb COV2-2196 bound well to both of the viral variants tested 176 (Fig S4D) . 177 We next assessed the neutralizing activity of COV2-2489 and COV2-2676 by FRNT on 178 additional cell lines: MA104 cells, HEK-293T cells ectopically expressing ACE2 (293T+ACE2), 179

and Vero cells ectopically expressing TMPRSS2 (Vero+TMPRSS2), in comparison to wild-type 180

Vero cells. For both mAbs, neutralization potency was greater on Vero cells than MA104 cells or 181 293T+ACE2 cells; both mAbs had weak neutralization potency when assessed using the latter 182 two cell types (Fig 3B) . TMPRSS2 over-expression did not alter the potency of the mAbs, as 183 neutralization assays using Vero+TMPRSS2 cells had similar potency to the parental wild-type 184 cell (Fig 3B) . These data indicate that mAbs against the NTD exhibit cell type-dependent 185 neutralization, which may be due to variable expression of entry factors and receptors on the 186 surface of different cell types. 187

To probe further the mechanism of neutralization of mAbs targeting the NTD, we 188 performed modified FRNTs, in which SARS2-CoV-2 was incubated with mAb before (pre-189 attachment FRNT) or after (post-attachment FRNT) virus was absorbed to the surface of Vero 190 cells. Both COV2-2489 and COV2-2676 efficiently neutralized SARS-CoV-2 when added 191 following virus absorption to the surface of cells (Fig 3C) . These data suggest that mAbs 192 targeting the NTD can neutralize SARS-CoV-2 at a post-attachment step of the viral life cycle in 193 Vero cells. 194 We also performed experiments that directly assessed the ability of NTD mAbs to block 195 virus attachment to Vero E6 cells and Vero overexpressing hACE2 and TMPRSS2 cells. When 196 hACE2 and TMPRSS2 were expressed in cells ectopically, greater SARS-CoV-2 attachment was 197 observed (Fig 3D, left panel) . Neither anti-NTD (COV2-2489 or COV2-2676) nor anti-RBD 198 15 nine days after inoculation. These results suggested that diversification of neutralizing antibody 290 responses after natural infection or vaccination (e.g., targeting of vulnerable RBD and NTD sites 291 of the spike) could be beneficial for protective immunity, with a potential implication for 292 therapeutic cocktail design. 293

Several research groups have identified RBD-specific mAbs using B cells from CoV-2 convalescent individuals, with a number of these mAbs now in Phase III clinical trials 296 (Baum et al., 2020a; Chen et al., 2020a; Jones et al., 2020) and two mAb products having 297 obtained Emergency Use Authorization from the U.S. Food and Drug Administration. Due to the 298 large number of natural variant viruses with polymorphisms in the RBD that are emerging, 299 identification of neutralizing and protective human mAbs that bind to other antigenic sites on the 300 S protein is warranted. In a large (n =389) panel of mAbs we isolated with reactivity to the 301 SARS-CoV-2 S protein, the majority of mAbs bound to S protein but not to the RBD (Zost et al., 302 2020b) . We found that a small subset of non-RBD antibodies that recognized the NTD could 303 neutralize SARS-CoV-2 infection and confer protection in a stringent hACE2 transgenic mouse 304 model of disease. 305

Our studies highlight the promising functional activities of NTD-specific mAbs. 306

Although these mAbs did not bind as avidly to recombinant S6P ecto protein as did the most potent 307 RBD-reactive mAbs we isolated, they neutralized SARS-CoV-2 with potencies comparable to 308 many RBD-targeting antibodies (Zost et al., 2020a; Zost et al., 2020b) . Very few NTD-targeting 309 neutralizing antibodies have been reported to date. Sequence comparison of recently published 310 NTD-reactive SARS-CoV-2 mAbs 4A8 (Chi et al., 2020) and 4-8 (Liu et al., 2020a) revealed 311 that our mAbs are genetically distinct and not members of a public clonotype matching those 312 mAbs (Table S1) . 313

Most neutralizing SARS-CoV-2 mAbs block RBD interactions with ACE2 (Brouwer et 314 al., 2020; Cao et al., 2020; Ju et al., 2020; Liu et al., 2020a; Rogers et al., 2020; Seydoux et al., 315 2020; Wec et al., 2020; Wu et al., 2020; Zost et al., 2020a; Zost et al., 2020b) . However, the 316 mechanism of neutralization of NTD-reactive antibodies appears complex. Our data suggest that 317 the anti-NTD antibodies COV2-2676 and COV2-2489 inhibit at a post-attachment phase of 318 infection and may block subsequent virus entry or fusion steps. In cells in which anti-RBD and 319 anti-NTD antibodies do not appear to block virus attachment (i.e., conventional Vero cells), both 320 groups inhibited at a post-attachment step. Virus attachment to cells can differ in diverse cells, 321 likely because of the capacity of SARS-CoV-2 to use multiple attachment factors including 322 heparan sulfates, hACE2, TAM receptors, and possibly other molecules (Cantuti-Castelvetri et 323 al., 2020; Chen et al., 2020b; Chiodo et al., 2020; Clausen et al., 2020; Gao and Zhang, 2020) . 324

The mechanism of attachment in Vero (monkey kidney) cells without human ACE2 transfection 325 is uncertain; attachment might be mediated by monkey ACE2 although this has not been 326 formally demonstrated. It is possible that the NTD antibodies block entry by indirectly 327 interfering with ACE2 binding through steric interference of the Fc region. In analogous 328 experiments with MERS-CoV, structural studies presented showed that the MERS-CoV mAb 329 7D10 could bind to the NTD of S protein of MERS-CoV and inhibit RBD-DPP4 interaction 330 through its light chain, which was close to the RBD (Zhou et al., 2019) . We tested that model 331 here but found that neither COV2-2676 nor COV2-2489 blocked ACE2 interaction with RBD in 332 soluble protein or in cell-surface-display assays. Antibody fragment studies using Fab, F(ab′) 2 333 and IgG forms of COV2-2676 and COV2-2489 showed that the Fab forms lost neutralizing 334 activity, possibly suggesting some blocking occurs indirectly by steric effects of the projecting 335 Fc region into the direction of the RBD as in the case for the MERS-CoV mAB 7D10 (Zhou et 336 al., 2019) . However, we did not obtain direct evidence for this mechanism. In cells expressing 337 high hACE2 levels, anti-RBD antibodies partially inhibited attachment of virus, but anti-NTD 338 antibodies did not. 339

To define the fine specificity of this protective epitope, we performed saturation alanine-340 scanning mutagenesis studies and identified critical residues for binding of COV2-2676 or 341 COV2-2489 mAbs in the NTD. We showed that SARS-CoV-2 S protein variants with mutations 342 at F140S and G142D, or R158S in the NTD conferred resistance to COV2-2676 or COV2-2489 respectively, using a chimeric replication-competent VSV expressing the SARS-CoV-2 S 344 protein. Consistent with these data, Weisblum et al. identified an NTD epitope (residues 148 to 345 151) , and mutations in this epitope enabled escape from neutralizing antibody activity in a donor 346 plasma specimen (Weisblum et al., 2020) . 347

We first tested the prophylactic efficacy of COV2-2676 or COV2-2489 in a well-defined 348 model of SARS-CoV-2 infection in hACE2-expressing transgenic mice (Winkler et al., 2020) . 349

Mice pre-treated with COV2-2676 or COV2-2489 mAbs exhibited substantially lower viral titers 350 than mice treated with an isotype-control mAb and offered complete protection against death in 351 this model. We also assessed the therapeutic potential of these mAbs in the same mouse model. 352

Each of the mAbs mediated a therapeutic effect when administered after infection. Although 353 several protection studies of anti-SARS-CoV-2 mAbs have been published, all of these 354 experiments used mAbs directed against the RBD (Baum et al., 2020a; Chen et al., 2020a; 355 Hassan et al., 2020; Zost et al., 2020a) . There is only limited precedence for 356 in vivo protection against SARS-CoV-2 infection or disease mediated by mAbs that react to S 357 protein regions outside the RBD (McCallum et al., 2021; Voss et al., 2020; . 358

IgG interactions with Fcγ receptors and complement contribute to antibody-dependent 359 viral clearance during many infections, including HIV-1, Ebola, influenza, and chikungunya 360 viruses (DiLillo et al., 2014; Fox et al., 2019; Halper-Stromberg et al., 2014; Lu et al., 2016) . 361

MAbs against SARS-CoV-1 and SARS-CoV-2 also can confer protective effects in part through 362 through Fc-mediated effector functions (Atyeo et al., 2020; Pinto et al., 2020; Schafer et al., 363 2021) . To test whether this was the case with our mAbs, we generated COV2-2676 and 2489 364 LALA-PG variant Fc versions. Indeed, Fc-mediated activity for NTD-specific mAbs did 365 contribute to protection in the models we tested. Animals in the LALA-PG mAb-treated mice 366 groups had increased viral burden and lost weight, but still survived viral challenge, suggesting 367 involvement of Fc-effector function dependent and independent mechanisms in the protection in 368 vivo conferred by anti-NTD mAbs. 369 SARS-CoV-2 continues to evolve, and its capacity to escape the activity of neutralizing 370 antibodies in current clinical development is not fully understood. The emergence of mutations at 371 E484K in South African strains is concerning, because this change can impact the neutralizing 372 activity of many RBD-specific mAbs and immune serum generated from convalescent subjects 373 (Avanzato et al., 2020; Greaney et al., 2021; Liu et al., 2020b; Oude Munnink et al., 2021; 374 Piccoli et al., 2020; Rambaut et al., 2020; Starr et al., 2020) . Moreover, the administration of 375 convalescent plasma with suboptimal levels of neutralizing antibodies might increase resistance 376 in circulating SARS-CoV-2 populations (Bloch, 2020) . Furthermore, candidate vaccines that 377 include only RBD antigens lack the ability to induce NTD-reactive neutralizing antibodies 378 (Laczko et al., 2020; Mulligan et al., 2020; Smith et al., 2020; . Antibody therapy 379 or vaccine approaches that target additional antigenic sites may limit escape and prevent 380 compromising of vaccine-or natural infection-induced immunity. A combination of RBD-and 381 NTD-reactive neutralizing mAbs may offer an attractive alternative approach to treatments that 382 target only RBD. The data presented here describing neutralization escape viruses suggests the 383 potential utility of using mAb cocktails to avoid selection of neutralization resistant viruses. control, mAb a day before virus inoculation (D-1). One day later, mice were inoculated 498 intranasally (i.n.) with 10 3 PFU of SARS-CoV-2. 499

A. Body weight change of mice over time. Data shows the mean ± S.E.M. compared to the 500 isotype control mAb for two independent experiments (n = 6 to 11 for each experimental 501 group; one-way ANOVA with Dunnett's post hoc test of area under the curve from 4 to 7 502 dpi: ns, not significant, * * p < 0.01, * * * * p < 0.000 1). 503

Tissues were harvested at 7 dpi from a subset of mice in A. Viral burden in the lung, nasal 504 wash, and heart was assessed by qRT-PCR of the N gene. Data shows the mean ± S.E.M. 505 compared between all groups for two independent experiments (n = 6 for each experimental 506 group; one-way ANOVA with Tukey's post hoc test: ns, not significant, * p < 0.05, * * p < 0.01, 507 * * * p < 0.001, * * * * p < 0.0001). Dashed line represents limit of detection of assay. 508 control mAb for two independent experiments (n = 4 to 8 for each experimental group; one-514 way ANOVA with Dunnett's post hoc test of area under the curve from 4 to 7 dpi: ns, not 515 significant, * * * p < 0.001, * * * * p < 0.0001). 516 E. Tissues were harvested at 7 dpi from mice in D. Viral burden in the lung, nasal wash, and 517 heart was assessed by qRT-PCR of the N gene. Data shows the mean ± S.E.M. compared 518 between all groups for two independent experiments (n = 4 to 8 for each experimental group; 519 one-way ANOVA with Tukey's post hoc test: ns, not significant, * p < 0.05, * * p < 0.01, * * * p < 520 0.001, * * * * p < 0.0001). 521 control mAb for two independent experiments (n = 6 to 11 for each experimental group; one-540 way ANOVA with Dunnett's post hoc test of area under the curve from 4 to 7 dpi: ns, not 541 significant, * * p < 0.01, * * * p <0.001, * * * * p < 0.0001). 542

Tissues were harvested at 7 dpi from a subset of mice in A. Viral burden in the lung, nasal 543 wash, and heart was assessed by qRT-PCR of the N gene. Data shows the mean ± S.E.M. 544 compared between all groups for two independent experiments (n = 6 to 7 for each 545 experimental group; one-way ANOVA with Tukey's post hoc test: ns, not significant, * p < 546 0.05, * * p < 0.01, * * * p < 0.001, * * * * p < 0.0001). 547 C. Heat map of cytokine and chemokine levels in lung homogenates harvested in B as measured 548 by a multiplex platform. Log 2 fold change compared to lungs from mock-infected animals 549 was plotted in the corresponding heat map (associated statistics are reported in Fig S6B) . Survival was compared to isotype control for two independent experiments (n = 6 to 14 for each 569 experimental group; log-rank Mantel-Cox test; * * * * p < 0.0001). 570 C. Tissues were harvested at 7 dpi mice from a subset of mice in B. Viral burden in the lung, 571 nasal wash, and heart was assessed by qRT-PCR of the N gene. Data shows the mean ± S.E.M. 572 compared between all groups for two independent experiments: n = 6 to 8 for each experimental 573 group; one-way ANOVA with Tukey's post hoc test: ns, not significant, * p < 0.05, * * * p <0.001). 574 D. Heat map of cytokine and chemokine levels in lung homogenates harvested in C as measured 575 by a multiplex platform. Log 2 fold change compared to lungs from mock-infected animals was 576 plotted in the corresponding heat map (associated statistics are reported in Fig S6C. ) Antibodies. The human antibodies studied in this paper were isolated from blood samples from 598 two individuals in North America with previous laboratory-confirmed symptomatic SARS-CoV-599 2 infection that was acquired in China. The original clinical studies to obtain specimens after 600 written informed consent were previously described (Zost et al., 2020b) recently (Liu et al., 2021) and also passaged in Vero-TMPRSS2 cells. The generation of a 630 replication-competent VSV expressing SARS-CoV-2 S protein with a 21 amino-acid C-terminal 631 deletion that replaces the VSV G protein (VSV-SARS-CoV-2) was described previously (Case et al., 632 2020b) . The S protein-expressing VSV virus was propagated in MA104 cell culture monolayers 633 (African green monkey, ATCC CRL-2378.1) as described previously (Case et al., 2020) , and viral 634 stocks were titrated on Vero E6 cell monolayer cultures. VSV plaques were visualized using neutral 635 red staining. All work with infectious SARS-CoV-2 was performed in Institutional Biosafety 636

Committee approved BSL3 and A-BSL3 facilities at Washington University School of Medicine 637 using appropriate positive pressure air respirators and protective equipment. conformation-stabilized SARS-CoV-2 S protein ectodomain (S6P ecto ) (Hsieh et al., 2020) was 652 synthesized and cloned into a DNA plasmid expression vector for mammalian cells. A similarly 653 designed S protein antigen with two prolines and removal of the furin cleavage site for 654 stabilization of the prefusion form of S (S2P ecto ) was reported previously (Wrapp et al., 2020) . In 655 brief, this gene includes the ectodomain of SARS-CoV-2 (to residue 1,208), a T4 fibritin 656 trimerization domain, an AviTag site-specific biotinylation sequence and a C-terminal 8× His 657 tag. To stabilize the construct in the pre-fusion conformation, we included substitutions F817P, 658 A892P, A899P, A942P, K986P and V987P and mutated the furin cleavage site at residues 682-659 685 from RRAR to ASVG. The recombinant S6P ecto protein was isolated by metal affinity 660 chromatography on HisTrap Excel columns (Cytiva), and protein preparations were purified 661 further by size-exclusion chromatography on a Superose 6 Increase 10/300 column (Cytiva). The 662 presence of trimeric, pre-fusion conformation S protein was verified by negative-stain electron 663 microscopy (Zost et al., 2020b) . For electron microscopy with S protein and Fabs, we expressed 664 a variant of S6P ecto lacking an AviTag but containing a C-terminal Twin-Strep-tag, similar to that 665 described previously (Zost et al., 2020b) . Expressed protein was isolated by metal affinity 666 chromatography on HisTrap Excel columns (Cytiva), followed by further purification on a 667

StrepTrap HP column (Cytiva) and size-exclusion chromatography on TSKgel 668 G4000SWXL (TOSOH). To express the RBD subdomain of the SARS-CoV-2 S protein, a 669 synthetic DNA (Twist Bioscience) encoding residues 319-541 was cloned into a mammalian 670 expression vector downstream of an IL-2 signal peptide and upstream of a thrombin cleavage 671 site, an AviTag and a 6× His tag. Recombinant SARS-CoV-2 S NTD protein was kindly 672 provided by P. McTamney, K. Ren and A. Barnes (AstraZeneca) . Purified proteins were 673 analyzed by SDS-PAGE to ensure purity and appropriate molecular weights. 674 675 MAb production and purification. Sequences of mAbs that had been synthesized (Twist 676 Bioscience) and cloned into an IgG1 monocistronic expression vector (designated as pTwist-677 mCis_G1) or Fab expression vector (designated as pTwist-mCis_FAB) were used for production 678 in mammalian cell culture. This vector contains an enhanced 2A sequence and GSG linker that 679 allows the simultaneous expression of mAb heavy and light chain genes from a single construct 680 upon transfection (Chng et al., 2015) . For antibody production, we performed transfection of 681

ExpiCHO cell cultures using the Gibco ExpiCHO Expression System as described by the vendor. 682

IgG molecules were purified from culture supernatants using HiTrap MabSelect SuRe (Cytiva) 683 on a 24-column parallel protein chromatography system (Protein BioSolutions). Fab proteins 684 were purified using CaptureSelect column (Thermo Fisher Scientific). Purified antibodies were 685 buffer-exchanged into PBS, concentrated using Amicon Ultra-4 50-kDa (IgG) or 30 kDa (Fab) 686 centrifugal filter units (Millipore Sigma) and stored at 4°C until use. F(ab′) 2 fragments were 687 generated after cleavage of IgG with IdeS protease (Promega) and then purified using TALON 688 metal affinity resin (Takara) to remove the enzyme and protein A agarose (Pierce) to remove the 689 Fc fragment. Purified mAbs were tested routinely for endotoxin levels (found to be less than 30 690 EU per mg IgG). Endotoxin testing was performed using the PTS201F cartridge (Charles River), 691 with a sensitivity range from 10 to 0.1 EU per mL, and an Endosafe Nexgen-MCS instrument 692 (Charles River). The bound antibodies were detected using goat anti-human IgG conjugated with horseradish 699 peroxidase (HRP) (Southern Biotech, cat. 2040-05, lot B3919-XD29, 1:5,000 dilution) and a 700 3,3′,5,5′-tetramethylbenzidine (TMB) substrate (Thermo Fisher Scientific). Color development 701 was monitored, 1M HCl was added to stop the reaction, and the absorbance was measured at 450 702 nm using a spectrophotometer (Biotek). For dose-response assays, serial dilutions of purified 703 mAbs were applied to the wells in triplicate, and antibody binding was detected as detailed 704 above. EC 50 values for binding were determined using Prism v.8.0 software (GraphPad) after log 705 transformation of the mAb concentration using sigmoidal dose-response nonlinear regression 706 analysis. 707 708

Wells of 384-well microtiter plates were coated with 1 µg/mL purified SARS-CoV-2 S6P ecto 710 protein at 4°C overnight. Plates were blocked with 2% BSA in DPBS-T for 1 h. Plasma or serum 711 samples were diluted in blocking buffer two-fold starting from a 1:10 sample dilution, added to 712 the wells (20 µL per well) in triplicate and incubated for 1 h at ambient temperature. For self-713 blocking controls, unlabelled mAbs COV2-2676 or COV2-2489 were added at 10 µg/mL to 714 separate wells coated with S6P ecto . Serum from a donor without an exposure history to SARS-715

CoV-2 was used as a negative control. A biotinylated mAb COV2-2676 or COV2-2489 was 716 added to the respective wells at 2.5 µg/mL in a volume of 5 µL per well (final concentration of 717 biotinylated mAb 0.5 µg/mL) without washing of unlabelled antibody, and then incubated for 30 718 min at ambient temperature. Binding of biotinylated mAb COV2-2676 or COV2-2489 alone to 719 S6P ecto served as a control for maximum binding. Plates were washed, and bound antibodies 720 were detected using HRP-conjugated avidin ( incubated with mAd dilutions for 1 h at 4°C. Virus then was allowed to internalize for 30 min at 770 37°C, and subsequently cells were overlaid with methylcellulose as described above. Thirty 771 hours later, the plates were fixed with 4% PFA and analyzed for antigen-specific foci as 772 described above for FRNTs. 773 774 Attachment inhibition assay. SARS-COV-2 was incubated with mAbs at the specified 775 concentration for 1 h at 4°C. The mixture was added to pre-chilled Vero or 776

Vero+ACE2+TMPRSS2 cells at an MOI of 0.005 and incubated at 4°C for 1 h. Cells were 777 washed six times with chilled PBS before addition of lysis buffer and extraction of RNA using 778

MagMax viral RNA isolation kit (Thermo Fisher Scientific) and a Kingfisher Flex 96-well 779 extraction machine (Thermo Fisher Scientific). SARS-CoV-2 RNA was quantified by qRT-PCR 780 using the N-specific primer/ probe set described below. Viral RNA levels were normalized to 781 GAPDH, and the fold change was compared with isotype control mAb. 782 783 Human ACE2 binding inhibition analysis. Wells of 384-well microtiter plates were coated 784 with 1 µg/mL purified recombinant SARS-CoV-2 S2P ecto protein at 4°C overnight. Plates were 785 blocked with 2% non-fat dry milk and 2% normal goat serum in DPBS-T for 1 h. For screening 786 J o u r n a l P r e -p r o o f 40 assays, purified mAbs from microscale expression were diluted two-fold in blocking buffer 787 starting from 10 µg/mL in triplicate, added to the wells (20 µL per well) and incubated for 1 h at 788 ambient temperature. Recombinant human ACE2 with a C-terminal Flag tag peptide was added 789 to wells at 2 µg/mL in a 5 µL per well volume (final 0.4 µg/mL concentration of human ACE2) 790 without washing of antibody and then incubated for 40 min at ambient temperature. Plates were 791 washed and bound human ACE2 was detected using HRP-conjugated anti-Flag antibody (Sigma-792 Aldrich, cat. A8592, lot SLBV3799, 1:5,000 dilution) and TMB substrate. ACE2 binding 793 without antibody served as a control. The signal obtained for binding of the human ACE2 in the 794

presence of each dilution of tested antibody was expressed as a percentage of the human ACE2 795 binding without antibody after subtracting the background signal. For dose-response assays, 796 serial dilutions of purified mAbs were applied to the wells in triplicate, and mAb binding was 797 detected as detailed above. IC 50 values for inhibition by mAb of S2P ecto protein binding to human 798 ACE2 was determined after log transformation of antibody concentration using sigmoidal dose-799 response nonlinear regression analysis. 800 801 Electron microscopy negative stain grid preparation, imaging and processing of S6P ecto -802 Fab complexes. To perform electron microscopy imaging, Fabs were recombinantly expressed 803 and purified or produced by digesting recombinant chromatography-purified IgGs using resin-804 immobilized cysteine protease enzyme (FabALACTICA, Genovis). The digestion occurred in 805 100 mM sodium phosphate and 150 mM NaCl pH 7.2 (PBS) for around 16 h at ambient 806 temperature. To remove cleaved Fc from intact IgG, the digestion mix was incubated with 807

CaptureSelect Fc resin (Genovis) for 30 min at ambient temperature in PBS buffer. If needed, the 808 Fab was buffer-exchanged into Tris buffer by centrifugation with a Zeba spin column (Thermo 809 Fisher Scientific). 810 811 For screening and imaging of negatively-stained SARS-CoV-2 S6P ecto protein in complex with 812 human Fabs, the proteins were incubated at an Fab:spike monomer molar ratio of 4:3 for about 1 813 hour at ambient temperature, and approximately 3 µL of the sample at concentrations of about 814 10-15 µg/mL was applied to a glow-discharged grid with continuous carbon film on 400 square 815 mesh copper electron microscopy grids (Electron Microscopy Sciences). The grids were stained 816 with 0.75% uranyl formate (Ohi et al., 2004) . Images were recorded on a Gatan US4000 4k × 4k 817 CCD camera using an FEI TF20 (TFS) transmission electron microscope operated at 200 keV 818 and control with Serial EM. All images were taken at 50,000× magnification with a pixel size of 819 2.18 Å per pixel in low-dose mode at a defocus of 1.5 to 1.8 µm. The total dose for the 820 micrographs was around 30e− per Å2. Image processing was performed using the cryoSPARC 821 software package. Images were imported, CTF-estimated and particles were picked. The 822 particles were extracted with a box size of 256 pixels and binned to 128 pixels. 2D class averages 823 were performed and good classes selected for ab initio model and refinement without symmetry. 824

Model docking to the EM map was done in Chimera (Pettersen et al., 2004) . For SARS-CoV-2 825 S6P ecto protein, the closed model (PDB:7JJI) was used and PDB:12E8 was used for the Fab (see 826 also Table S2 for details). 827 828 Epitope mapping of antibodies by alanine-scanning mutagenesis. Epitope mapping was 829 performed essentially as described previously (Davidson and Doranz, 2014 ) using a SARS-CoV-830 2 (strain Wuhan-Hu-1) spike protein NTD shotgun mutagenesis mutation library, made using a 831 full-length expression construct for spike protein, where 215 residues of the NTD (between spike 832 residues 9 and 310) were mutated individually to alanine, and alanine residues to serine. were compared to each other or the isotype control using a one-way ANOVA with Tukey's or 957

Dunnett's post hoc test, respectively, using Prism v.9.0 (GraphPad). Survival curves were 958 estimated using the Kaplan-Meier method and differences assessed using the log-rank Mantel-959

Cox test and a Bonferroni correction for multiple comparisons using Prism v.9.0 (GraphPad). 960 MCP-1 G-CSF IL-15 IL-9 IL-6 IL-4 IL-2 MIP-2 MCP-1 LIF IP-10 IFN-γ TNF-α α 0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 Ngene (log10 copies/mg) Ngene (log10 copies/mL)

A Potently Neutralizing Antibody Protects Mice 1036 against SARS-CoV-2 Infection

Distinct Early Serological Signatures Track

CoV-2 Survival

Case Study: Prolonged Infectious 1044

SARS-CoV-2 Shedding from an Asymptomatic Immunocompromised Individual with Cancer

Structures of Human 1049

Antibodies Bound to SARS-CoV-2 Spike Reveal Common Epitopes and Recurrent Features of 1050

REGN-COV2 antibodies prevent and treat SARS-1054

CoV-2 infection in rhesus macaques and hamsters

Antibody cocktail to SARS-CoV-2 spike protein prevents 1058 rapid mutational escape seen with individual antibodies

Convalescent plasma to treat COVID-19

Potent neutralizing 1064 antibodies from COVID-19 patients define multiple targets of vulnerability

Neuropilin-1 facilitates SARS-CoV-1069 2 cell entry and infectivity

Potent Neutralizing Antibodies against SARS-CoV-2 Identified by High-1073

Throughput Single-Cell Sequencing of Convalescent Patients' B Cells

Growth, detection, 1076 quantification, and inactivation of SARS-CoV-2

Neutralizing Antibody and Soluble ACE2 Inhibition of a 1080

Replication-Competent VSV-SARS-CoV-2 and a Clinical Isolate of SARS-CoV-2

SARS-CoV-2 Neutralizing Antibody LY-CoV555 in 1085 Outpatients with Covid-19

Virus load and virus shedding of SARS-CoV-2 and their impact 1089 on patient outcomes

A neutralizing human antibody binds to the N-terminal domain of the Spike 1093 protein of SARS-CoV-2

Independent Carbohydrate-Binding of SARS-CoV-2 Spike Protein to Host Lectins and Lung 1098

Cleavage efficient 2A peptides for high level monoclonal antibody expression in CHO 1102 cells

Persistence and Evolution of SARS-CoV-2 in an 1106

Immunocompromised Host

SARS-CoV-2 Infection Depends on 1110

Cellular Heparan Sulfate and ACE2

A high-throughput shotgun mutagenesis approach to 1113 mapping B-cell antibody epitopes

Broadly neutralizing 1116 hemagglutinin stalk-specific antibodies require FcgammaR interactions for protection against 1117 influenza virus in vivo

Optimal therapeutic activity of monoclonal antibodies 1121 against chikungunya virus requires Fc-FcgammaR interaction on monocytes

ACE2 partially dictates the host range and tropism of SARS-1125

Integrated pipeline for the accelerated discovery 1129 of antiviral antibody therapeutics

Analysis of a Therapeutic Antibody Cocktail 1133

Reveals Determinants for Cooperative and Broad Ebolavirus Neutralization

Human angiotensin-converting enzyme 2 1138 transgenic mice infected with SARS-CoV-2 develop severe and fatal respiratory disease

Complete Mapping of Mutations to 1143 the SARS-CoV-2 Spike Receptor-Binding Domain that Escape Antibody Recognition

Broadly neutralizing 1148 antibodies and viral inducers decrease rebound from HIV-1 latent reservoirs in humanized mice

Studies in humanized mice and convalescent humans yield a 1153 SARS-CoV-2 antibody cocktail

Isolation and characterization of SARS-CoV-2 from the 1157 first US COVID-19 patient

Severe Acute Respiratory Syndrome Coronavirus 2 from 1161 Patient with Coronavirus Disease, United States

A SARS-CoV-2 Infection Model in 1165

Mice Demonstrates Protection by Neutralizing Antibodies

SARS-CoV-2 D614G variant exhibits 1169 efficient replication ex vivo and transmission in vivo

Structure-based design of prefusion

SARS-CoV-2 spikes

LY-CoV555, a rapidly 1177 isolated potent neutralizing antibody, provides protection in a non-human primate model of 1178 SARS-CoV-2 infection

Human neutralizing antibodies elicited by SARS-CoV-2 infection

Recurrent emergence and transmission of a SARS-CoV-2 Spike deletion ∆H69/V70. 1185 bioRxiv 20201214422555

A Single Immunization with 1189

Nucleoside-modified mRNA vaccines elicits strong cellular and humoral immune responses 1190 against SARS-CoV-2 in mice

Potent neutralizing antibodies against multiple epitopes on SARS-1194

CoV-2 spike

Neutralizing activity of BNT162b2-elicited serum -1198 preliminary report

Syndrome Coronavirus 2

HIV-1-infected cells by broadly neutralizing antibodies against HIV-1 in vivo

Human Fc gamma RI and Fc gamma RII interact 1211 with distinct but overlapping sites on human IgG

N-terminal domain antigenic mapping reveals a site 1215 of vulnerability for SARS-CoV-2. bioRxiv

Natural deletions in the SARS-CoV-2 spike glycoprotein drive 1219 antibody escape

Enhancing dengue virus maturation using a stable furin over-expressing cell line

Phase I/II study of COVID-19 RNA vaccine 1227

BNT162b1 in adults

Negative Staining and Image Classification -1230

Powerful Tools in Modern Electron Microscopy

Lethality of SARS-CoV-2 1234 infection in K18 human angiotensin-converting enzyme 2 transgenic mice

Transmission of SARS-CoV-2 on mink farms between humans and mink and back to humans

UCSF Chimera--a visualization system for exploratory research and 1244 analysis

Mapping Neutralizing and 1248

Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by Structure-1249

Cross-neutralization of SARS-CoV-2 by a 1253 human monoclonal SARS-CoV antibody

Spike mutation D614G alters SARS-CoV-2 1257 fitness

A dynamic nomenclature proposal for SARS-CoV-2 lineages to assist 1261 genomic epidemiology

Convergent antibody responses to SARS-1265

CoV-2 in convalescent individuals

Isolation of potent SARS-CoV-2 neutralizing antibodies and 1269 protection from disease in a small animal model

Antibody potency, effector function, 1273 and combinations in protection and therapy for SARS-CoV-2 infection in vivo

Analysis of a SARS-CoV-2-Infected 1278

Individual Reveals Development of Potent Neutralizing Antibodies with Limited Somatic 1279

Landscape and Selection of Vaccine Epitopes in SARS-1283

CoV-2. bioRxiv 101101

Prospective mapping of viral mutations that escape antibodies used 1287 to treat COVID-19. bioRxiv

Emergence and rapid spread of a new severe 1291 acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) lineage with multiple spike 1292 mutations in South Africa. medRxiv

Human monoclonal antibody 1297 combination against SARS coronavirus: synergy and coverage of escape mutants

Prevalent, protective, and convergent IgG 1302 recognition of SARS-CoV-2 non-RBD spike epitopes in COVID-19 convalescent plasma

A human monoclonal antibody 1307 blocking SARS-CoV-2 infection

Broad neutralization of SARS-related viruses 1311 by human monoclonal antibodies

Escape from neutralizing 1315 antibodies by SARS-CoV-2 spike protein variants

The IgG Fc 1318 contains distinct Fc receptor (FcR) binding sites: the leukocyte receptors Fc gamma RI and Fc 1319

gamma RIIa bind to a region in the Fc distinct from that recognized by neonatal FcR and protein 1320

SARS-CoV-2 infection of human ACE2-transgenic mice 1324 causes severe lung inflammation and impaired function

Cryo-EM structure of the 2019-nCoV spike in the prefusion 1328 conformation

An Alternative Binding Mode

Antibodies to the SARS-CoV-2 Receptor Binding Domain

DNA vaccine protection

CoV-2 in rhesus macaques

A proof of concept for neutralizing antibody-guided vaccine 1340 design against SARS-CoV-2. bioRxiv

Structural definition of a neutralization epitope on the N-terminal domain of 1344

Potently neutralizing and protective human 1348 antibodies against SARS-CoV-2

Rapid isolation and profiling of a diverse panel of 1352 human monoclonal antibodies targeting the SARS-CoV-2 spike protein

(QIAGEN) from aliquots of supernatant containing a suspension of the selected virus population. 878The S protein gene cDNA was amplified with a SuperScript IV One-Step RT-PCR kit (Thermo 879 Fisher Scientific) using primers flanking the S gene. The amplified PCR product (4,000 bp) was 880 purified using SPRI magnetic beads (Beckman Coulter) at a 1:1 ratio and sequenced by the 881 Sanger sequence technique using primers giving forward and reverse reads of the NTD. isolates, experiments were performed as above, with the modification of using Vero TMPRSS2 892 cells. 893 894 Protection against wild-type SARS-CoV-2 in mice. Male and female heterozygous K18-hACE 895 C57BL/6J mice were housed in groups of up to 5 mice per cage at 18 to 24°C ambient temperatures 896 and 40 to 60% humidity. Mice were fed a 20% protein diet (PicoLab 5053, Purina) and maintained 897 on a 12-h light-dark cycle (06:00 to 18:00). Food and water were available ad libitum. Mice (8 to 9 898 weeks old) were inoculated with 1 × 10 3 PFU of SARS-CoV-2 via the intranasal route. Anti-SARS-899CoV-2 human mAbs or isotype control mABS were administered 24 h before (prophylaxis) or 24 h 900 J o u r n a l P r e -p r o o f 45 or 48 h after (therapy) SARS-CoV-2 inoculation. Weights and lethality were monitored on a daily 901 basis for up to 14 days after inoculation and a subset of mice were euthanized at 7 dpi and tissues 902 were collected. 903 904 Measurement of viral burden. For RT-qPCR, mouse tissues were weighed and homogenized 905 with zirconia beads in a MagNA Lyser instrument (Roche Life Science) in 1 mL of DMEM 906 medium supplemented with 2% heat-inactivated FBS. Tissue homogenates were clarified by 907 centrifugation at 10,000 rpm for 5 min and stored at −80°C. RNA was extracted using a 908MagMax mirVana Total RNA isolation kit (Thermo Fisher Scientific) and a Kingfisher Flex 96-909 well extraction machine (Thermo Fisher Scientific). RNA was reverse transcribed and amplified 910 using the TaqMan RNA-to-CT 1-Step Kit (ThermoFisher). RNA levels were measured by one-911 step quantitative reverse transcriptase PCR (qRT-PCR) assay as previously described (Hassan et 912 al., 2020) . A TaqMan assay was designed to target the N gene, as previously described ( Cytokine and chemokine levels in the lungs of SARS-CoV-2 infected mice at 7 dpi following d-1017 1 treatment with isotype, COV2-2381, COV2-2676, and COV2-2676 LALA PG as measured by 1018 a multiplex platform (two independent experiments, n = 6 per group. One-way ANOVA with 1019Tukey's post hoc test: ns, not significant, * p < 0.05, * * p < 0.01, * * * p < 0.001, * * * * p < 0.0001.) 1020 Cytokine and chemokine levels in the lungs of SARS-CoV-2 infected mice at 7 dpi following 1023 d+1 treatment with isotype, COV2-2381, COV2-2676, and COV2-2676 LALA PG as measured 1024 by a multiplex platform (two independent experiments, n = 6 per group. One-way ANOVA with 1025Tukey's post hoc test: ns, not significant, * p < 0.05, * * p < 0.01, * * * p < 0.001, * * * * p < 0.0001.) 1026

Related to Figures 5 and 6 . 1028Cytokine and chemokine levels in the lungs of SARS-CoV-2 infected mice at 7 dpi following 1029 d+1 treatment with isotype, COV2-2381, COV2-2676, and COV2-2676 LALA PG as measured 1030 by a multiplex platform (two independent experiments, n = 6 per group. One-way ANOVA with 1031Tukey's post hoc test: ns, not significant, * p < 0.05, * * p < 0.01, * * * p < 0.001, * * * * p < 0.0001.) 1032